Rosetta Genomics Ltd. (USA)  

(Public, NASDAQ:ROSG)   Watch this stock  
Find more results for ROSG
+0.03 (1.23%)
Sep 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.38 - 2.50
52 week 2.07 - 5.55
Open 2.50
Vol / Avg. 0.00/79,495.00
Mkt cap 35.68M
P/E     -
Div/yield     -
EPS -0.98
Shares 14.50M
Beta -3.88
Inst. own 3%
Sep 16, 2015
Half Year 2015 Rosetta Genomics Ltd Earnings Release (Estimated) Add to calendar
Sep 9, 2015
Rosetta Genomics Ltd at Rodman & Renshaw Global Investment Conference - 5:05PM EDT - Add to calendar
Jul 8, 2015
Rosetta Genomics Ltd at Cantor Fitzgerald Inaugural Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -949.81% -1094.65%
Operating margin -907.12% -1074.00%
EBITD margin - -1051.47%
Return on average assets -75.19% -67.32%
Return on average equity -83.82% -75.07%
Employees 52 -
CDP Score - -


10 Plaut Street, Science Park, POB 4059
REHOVOT, 7670609
+972-7-32220700 (Phone)
+972-7-32220701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Rosetta Genomics Ltd. is a molecular diagnostics company engaged in developing microRNA-based diagnostics discovered and developed through its microRNAs and platform technologies. The Company has established a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory in Philadelphia, which enables it to commercialize its diagnostic tests applying its microRNA technology. It has developed platform technologies for the identification, extraction, quantification, and analysis of microRNAs from a wide range of sample types. These technologies enable the identification and advancement of multiple diagnostic projects addressing critical unmet needs in cancer, cardiovascular diseases and other indications. The Company’s products are Rosetta Cancer Origin Test (formerly miRview mets2), Rosetta Mesothelioma Test (formerly miRview meso), Rosetta Lung Cancer Test (formerly miRview lung) and Rosetta Kidney Cancer Test (formerly miRview kidney).

Officers and directors

Brian A. Markison Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
Kenneth A. Berlin President, Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Ron Kalfus Chief Financial Officer
Age: 40
Bio & Compensation  - Reuters
Douglas Sites Executive Vice President - Sales and Marketing
Bio & Compensation  - Reuters
Dganit Bar Ph.D. Chief Scientific Officer
Age: 46
Bio & Compensation  - Reuters
Eti Meiri Ph.D. Vice President - Research
Age: 46
Bio & Compensation  - Reuters
Oded Biran General Counsel
Age: 36
Bio & Compensation  - Reuters
E. Robert Wassman M.D. Chief Medical Officer
Age: 64
Bio & Compensation  - Reuters
Kevin Watson Director, Reimbursement-Managed Care
Bio & Compensation  - Reuters
Roy N. Davis Director
Age: 68
Bio & Compensation  - Reuters